Posted by Michael Wonder on 30 Nov 2021
Hepion Pharmaceuticals receives FDA fast track designation for CRV431 for the treatment of NASH
30 November 2021 - Hepion Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for the Company’s lead drug candidate, CRV431, for the treatment of NASH.
CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes.
